MX2023014281A - Lipidos novedosos. - Google Patents

Lipidos novedosos.

Info

Publication number
MX2023014281A
MX2023014281A MX2023014281A MX2023014281A MX2023014281A MX 2023014281 A MX2023014281 A MX 2023014281A MX 2023014281 A MX2023014281 A MX 2023014281A MX 2023014281 A MX2023014281 A MX 2023014281A MX 2023014281 A MX2023014281 A MX 2023014281A
Authority
MX
Mexico
Prior art keywords
novel lipids
lipids
novel
present
invention includes
Prior art date
Application number
MX2023014281A
Other languages
English (en)
Inventor
Daniel Emil Levy
Annie Bouchard
James Mcchesney
Saravanan Kappusamy
John Kallikat Augustine
Original Assignee
Signpath Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Signpath Pharma Inc filed Critical Signpath Pharma Inc
Publication of MX2023014281A publication Critical patent/MX2023014281A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/08—Esters of oxyacids of phosphorus
    • C07F9/09—Esters of phosphoric acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/08—Esters of oxyacids of phosphorus
    • C07F9/09—Esters of phosphoric acids
    • C07F9/091—Esters of phosphoric acids with hydroxyalkyl compounds with further substituents on alkyl
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/655—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms
    • C07F9/65515—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms the oxygen atom being part of a five-membered ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

La presente invención incluye un compuesto que tiene la siguiente fórmula estructural: (ver Fórmula).
MX2023014281A 2018-06-26 2020-12-17 Lipidos novedosos. MX2023014281A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862690196P 2018-06-26 2018-06-26
US16/452,858 US10975111B2 (en) 2018-06-26 2019-06-26 Cardiopathy-reducing phosphodiester lipids

Publications (1)

Publication Number Publication Date
MX2023014281A true MX2023014281A (es) 2024-01-17

Family

ID=68980509

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2020014097A MX2020014097A (es) 2018-06-26 2019-06-26 Lipidos novedosos.
MX2023014281A MX2023014281A (es) 2018-06-26 2020-12-17 Lipidos novedosos.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2020014097A MX2020014097A (es) 2018-06-26 2019-06-26 Lipidos novedosos.

Country Status (10)

Country Link
US (3) US10975111B2 (es)
EP (1) EP3813820A4 (es)
JP (2) JP7325840B2 (es)
KR (1) KR102627389B1 (es)
CN (1) CN112367986A (es)
AU (2) AU2019291808A1 (es)
CA (1) CA3103918C (es)
MX (2) MX2020014097A (es)
TW (1) TWI731336B (es)
WO (1) WO2020006033A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20190008878A1 (en) * 2017-07-07 2019-01-10 Signpath Pharma Inc. Compositions and method for reducing cardiotoxicity
TWI731336B (zh) 2018-06-26 2021-06-21 美商標徑製藥公司 新穎脂質
US11696902B2 (en) 2018-08-14 2023-07-11 AltaThera Pharmaceuticals, LLC Method of initiating and escalating sotalol hydrochloride dosing
US11610660B1 (en) 2021-08-20 2023-03-21 AltaThera Pharmaceuticals LLC Antiarrhythmic drug dosing methods, medical devices, and systems
US20240091242A1 (en) * 2021-01-29 2024-03-21 Signpath Pharma, Inc. Lipids that reduce lung damage, improve pulmonary function and decrease pro-inflammatory cytokines
JP2024508884A (ja) * 2021-03-03 2024-02-28 サインパス ファルマ，インク． ヒトにおける悪性胸水に対する治療
TW202417005A (zh) * 2022-09-22 2024-05-01 美商標徑製藥公司 保護心臟之脂質及使用方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005049587A1 (en) * 2003-11-21 2005-06-02 Ranbaxy Laboratories Limited Process for preparation of biphenyl tetrazole
JP2008519058A (ja) 2004-11-08 2008-06-05 ネオファーム、インコーポレイティッド カルジオリピン類似体の合成及びそれらの使用
US10532045B2 (en) 2013-12-18 2020-01-14 Signpath Pharma, Inc. Liposomal mitigation of drug-induced inhibition of the cardiac IKr channel
US10117881B2 (en) * 2011-06-03 2018-11-06 Signpath Pharma, Inc. Protective effect of DMPC, DMPG, DMPC/DMPG, LYSOPG and LYSOPC against drugs that cause channelopathies
JP2017516813A (ja) 2014-06-03 2017-06-22 サインパス ファルマ, インク.Signpath Pharma, Inc. チャネル病を引き起こす薬物に対するｄｍｐｃ、ｄｍｐｇ、ｄｍｐｃ／ｄｍｐｇ、ｅｇｐｇ、ｌｙｓｏｐｇ及びｌｙｓｏｐｃの防御効果
CN105273001A (zh) 2014-07-21 2016-01-27 南京绿叶制药有限公司 一种合成磷脂酰甘油单钠盐的方法
CN105985373A (zh) 2015-04-10 2016-10-05 江苏东南纳米材料有限公司 一种制备（r）-1,2-二脂肪酸甘油磷酯酰甘油酯的新方法
CN106188169B (zh) * 2016-07-07 2019-06-25 沈阳药科大学 一种含有唾液酸基团的脂质衍生物的合成及其在药物制剂中的应用
US20190008878A1 (en) * 2017-07-07 2019-01-10 Signpath Pharma Inc. Compositions and method for reducing cardiotoxicity
TWI731336B (zh) 2018-06-26 2021-06-21 美商標徑製藥公司 新穎脂質

Also Published As

Publication number Publication date
CN112367986A (zh) 2021-02-12
EP3813820A4 (en) 2022-05-04
CA3103918C (en) 2023-09-19
US10975111B2 (en) 2021-04-13
KR20210018926A (ko) 2021-02-18
WO2020006033A1 (en) 2020-01-02
CA3103918A1 (en) 2020-01-02
JP2023153882A (ja) 2023-10-18
TW202019404A (zh) 2020-06-01
TWI731336B (zh) 2021-06-21
KR102627389B1 (ko) 2024-01-19
US20190389888A1 (en) 2019-12-26
US11746119B2 (en) 2023-09-05
JP7325840B2 (ja) 2023-08-15
US20220056057A1 (en) 2022-02-24
MX2020014097A (es) 2021-04-13
US11643424B2 (en) 2023-05-09
AU2019291808A1 (en) 2021-01-14
AU2022205275B2 (en) 2024-05-30
AU2022205275A1 (en) 2022-08-11
EP3813820A1 (en) 2021-05-05
JP2021534076A (ja) 2021-12-09
US20210198294A1 (en) 2021-07-01

Similar Documents

Publication Publication Date Title
MX2023014281A (es) Lipidos novedosos.
ZA202102549B (en) Substituted tolyl as fungicides
CL2022000448A1 (es) Autoinyector (divisional solicitud no. 201903061)
PH12018501096A1 (en) Modulators of chemokine receptors
PH12020500655A1 (en) Compounds
AU2018258581A8 (en) RAF-degrading conjugate compounds
MX2018006148A (es) Inhibidores de cxcr2.
EA201992177A1 (ru) Композиции на основе нирапариба
AU2018293627A1 (en) New azaquinoline derivatives
CA185542S (en) Table
MX2020010657A (es) Derivados de oxadiazolina.
MX2021012440A (es) Farmacos precursores de oxabicicloheptanos.
ZA202309446B (en) Rapamycin analogs and uses thereof
PH12021550102A1 (en) Cardiosafe antidiabetic therapy
SG10201805896SA (en) PPARγ AGONISTS FOR TREATMENT OF MULTIPLE SCLEROSIS
EA202190475A1 (ru) Мини-gde для лечения гликогеноза iii типа
ZA202101487B (en) Novel compounds
EA201991241A1 (ru) Способ получения метоксиметилпиридин дикарбоксилата
MX2018011877A (es) Proceso mejorado para la preparacion de tartrato de butorfanol.
MX2019004182A (es) Proceso para la fabricacion de 2,6-dimetil-5-hepten-1-al.
MX2021001904A (es) Formas solidas de benzoxaborol sustituido y composiciones de las mismas.
MX2018003903A (es) Compuesto biciclico y uso del mismo para inhibicion de suv39h2.
MX2019008375A (es) Tiobenzoimidazol como fungicidas.
MY188420A (en) Crystalline forms of (s)-afoxolaner
MX2020008689A (es) Composicion herbicida que comprende por lo menos un compuesto activo fenolico.